secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0000950170-22-014801
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector Q2 net income $9.9M, cash $808.9M; AL044 IND submitted
--------------------------------------------------------------

- Net income $9.9M ($0.12/share) vs net loss $55.1M ($0.69) in Q2 2021; collaboration revenue rose to $79.9M from $6.6M.
- Cash, equivalents and investments $808.9M; estimated runway into second half of 2024.
- IND submitted for AL044 targeting MS4A, a genetic risk locus for Alzheimer's; first study in healthy volunteers planned.
- Expanding sites for INFRONT-3 Phase 3 of latozinemab in FTD-GRN; Phase 1 data for AL101 expected later 2022.
- Peter Heutink appointed CSO; John Maraganore as strategic advisor; AbbVie terminates CD33 collaboration (AL003).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022014801/0000950170-22-014801-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017022014801/alec-20220804.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-014801

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer